Scholar Rock Holding Corp
SRRK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SRRK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SRRK
Scholar Rock Holding Corp (SRRK) is a biopharmaceutical company focused on developing therapies that inhibit myostatin activation, with its lead candidate apitegromab in clinical trials for spinal muscular atrophy (SMA) and other neuromuscular disorders.
Key risk: Capital needs for development
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 6 clinical trials for Scholar Rock Holding Corp.
Scholar Rock Holding Corp (SRRK) is a biopharmaceutical company focused on developing therapies that inhibit myostatin activation, with its lead candidate apitegromab in clinical trials for spinal muscular atrophy (SMA) and other neuromuscular disorders.
- Lead candidate apitegromab is being developed for SMA, with ongoing Phase 2 OPAL trial and planned Phase 2 FORGE trial in FSHD [sec_mda · as of 2026-05-07].
- Cash, cash equivalents, and marketable securities of $440.9M as of 2026-06-30 [sec].
- Net loss of $109.9M for the three months ended June 30, 2026 [sec].
- Accumulated deficit of $1.4 billion as of March 31, 2026 [sec_mda · as of 2026-05-07].
- Company expects existing cash to fund operations into 2027 but will need additional capital to complete clinical development and commercialization [sec_mda · as of 2026-05-07].
What works
- Apitegromab targets a novel mechanism—selective inhibition of myostatin activation—which may offer therapeutic benefit across multiple neuromuscular disorders beyond SMA [sec_mda · as of 2026-05-07].
- The company has a robust pipeline with multiple ongoing and planned trials, including the Phase 2 OPAL study in SMA patients under two years and the Phase 2 FORGE trial in FSHD [sec_mda · as of 2026-05-07].
- Scholar Rock has a cash runway into 2027, providing a multi-year operational buffer to advance key programs [sec_mda · as of 2026-05-07].
What to weigh
- The company has a history of significant operating losses, with an accumulated deficit of $1.4 billion as of March 31, 2026 [sec_mda · as of 2026-05-07].
- Scholar Rock will require additional capital to complete clinical development and commercialization for its current programs, and its cash runway assumptions may prove incorrect [sec_mda · as of 2026-05-07].
- The company faces the inherent risks of clinical-stage biotech, including potential regulatory setbacks and the need to secure marketing approval for apitegromab [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $1.4 billion as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $1.4 billion.”
SEC MD&A · May 7, 2026
The company is planning a Phase 2 FORGE trial in FSHD.
“our planned Phase 2 FORGE trial in FSHD patients”
SEC MD&A · May 7, 2026
Net loss was $105.5 million for the three months ended March 31, 2026.
“Our net losses were $105.5 million for the three months ended March 31, 2026.”
SEC MD&A · May 7, 2026
Risks & what to watch (3)›
Key risks
- Capital needs for development — Company will require additional capital to complete clinical development and commercialization for each current program [sec_mda · as of 2026-05-07].
- Clinical and regulatory risk — Apitegromab is still in clinical trials; regulatory approval is not guaranteed and could be delayed [sec_mda · as of 2026-05-07].
- Accumulated deficit — Accumulated deficit of $1.4 billion as of March 31, 2026, reflecting sustained operating losses [sec_mda · as of 2026-05-07].
What to watch
- Initiation and enrollment of the Phase 2 FORGE trial in FSHD [sec_mda · as of 2026-05-07].
- Progress of the Phase 2 OPAL study in SMA patients under two years of age [sec_mda · as of 2026-05-07].
- Any regulatory updates or interactions regarding apitegromab's marketing application [sec_mda · as of 2026-05-07].
- Cash burn rate and any future capital raises to extend runway beyond 2027 [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Scholar Rock Holding Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scholar Rock Holding Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.2 months
D/E 1.06 · 0% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
0 buys · 17 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
278
Total value held
$5.50B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 17,243,152 | $847.7M |
| vanguard capital management llc | 7,782,694 | $382.6M |
| blackrock, inc. | 7,469,293 | $367.2M |
| samsara biocapital, llc | 6,897,652 | $339.1M |
| wellington management group llp | 6,717,655 | $330.2M |
| janus henderson group plc | 4,473,674 | $219.8M |
| state street corp | 4,031,317 | $198.2M |
| bellevue group ag | 3,584,573 | $176.2M |
| jennison associates llc | 3,340,492 | $164.2M |
| woodline partners lp | 3,000,940 | $147.5M |
Showing top 10 of 278 institutional holders of Scholar Rock Holding Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 15.7%
- Days to cover
- 9.2
- Shares short
- 14,906,364
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SRRK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Scholar Rock Holding Corp?
Scholar Rock Holding Corp (SRRK) is a biopharmaceutical company focused on developing therapies that inhibit myostatin activation, with its lead candidate apitegromab in clinical trials for spinal muscular atrophy (SMA) and other neuromuscular disorders.
What is Scholar Rock Holding Corp's lead drug candidate?
Scholar Rock Holding Corp's most advanced tracked candidate is apitegromab (Phase 3) for SMA; Spinal Muscular Atrophy; Facioscapulohumeral Muscular Dystrophy.
Who is the CEO of Scholar Rock Holding Corp?
Mr. David L. Hallal is the chief executive officer of Scholar Rock Holding Corp (SRRK).
Where is Scholar Rock Holding Corp headquartered?
Scholar Rock Holding Corp (SRRK) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Scholar Rock Holding Corp focus on?
Scholar Rock Holding Corp develops therapies across Oncology, Rare Disease, Metabolic, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.